



On reflection, no other treatment looks so convenient

Many women with genital warts would welcome the convenience and dignity of treating themselves at home.

New Warticon Fem makes self-treatment practical by the simple inclusion of a mirror in every pack.

Proven to be effective¹ and well tolerated² when used in this way,

Warticon Fem is now a clear first choice treatment.

NEW
Warticon[®]
fem
Podophyllotoxin 0.5% w/v

Clearly simple enough for
self-application in female genital warts

ABBREVIATED PRESCRIBING INFORMATION Warticon, Warticon Fem: Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the topical treatment of condyloma acuminata affecting the penis or the female external genitalia. **Dosage and Administration:** The affected area should be thoroughly washed with soap and water, and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. If residual warts persist, this 3-day treatment may be repeated, at weekly intervals, if necessary, for a total of 4 weeks of treatment. The majority of patients will not require in excess of 30 loops for each application, however a maximum of 50 loops per application (equivalent to 250µl of Warticon Solution) may be applied. Where lesions are greater in area than 4cm², it is recommended that treatment takes place under the direct supervision of medical staff. **Contra-Indications, Warnings, etc:** Open wounds following surgical procedures should not be treated with podophyllotoxin. Hypersensitivity to podophyllotoxin is a contra-indication. Avoid contact with the eyes. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur on the second or third day of application associated with the start of wart necrosis. In the majority of cases the reactions are mild. Tenderness, smarting, erythema, superficial epithelial ulceration and balanoposthitis have been reported. Local irritation decreases after treatment. **Use in Pregnancy:** Do not use during pregnancy or lactation. **Overdosage:** There have been no reported overdoses with Warticon Solution. No specific antidote is known. Following accidental spillage, wash the skin well with soap and water. In the event of accidental ingestion give emetic or stomach washout. Treatment should be symptomatic and in severe oral overdose ensure the airway is clear and give fluids, check and correct electrolyte balance, monitor blood gases and liver function. Blood count should be monitored for at least five days. **Pharmaceutical Precautions:** Product should be stored at room temperature. **Legal Category:** POM. **Package Quantities:** Each bottle contains 3ml of Warticon Solution. Plastic applicators are also enclosed in each pack. Each loop will carry a volume of approximately 5µl Warticon Solution. Warticon Fem also contains a mirror to facilitate accurate application. **Basic NHS Cost:** Warticon 3ml £16.00, Warticon Fem 3ml £16.00. **Product Licence Number:** PL3863/0007 **Date of Preparation:** June 1993.

Your resource...

Sexually Transmitted Diseases is your resource for the most current, comprehensive information available on all aspects of sexually transmitted disease. Its unique, multidisciplinary perspective provides insight into the latest advances in the field.


- **Diagnosis and Treatment**
- **Etiology ■ Pathology**
- **Epidemiology ■ Microbiology**
- **Public Health and Behavior**

Published bi-monthly, *Sexually Transmitted Diseases* brings you original articles on newly identified syndromes, new investigations into the mechanism of disease, descriptions of clinical experiences and reports on therapeutic trials. Features include notes from the CDC, NIH and ASHA, case reports and AVDA news.

Subscribe to the resource you can rely on for the latest, most authoritative information on STDs!


for the latest information on *Sexually Transmitted Diseases*

Journal of the American Venereal Disease Association
Julius Schachter, PhD, Editor



No-Risk Guarantee!

If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.



☎ Call us today TOLL FREE
1-800-777-2295 (U.S. except AK)
or FAX your order 301-824-7390.

Published bi-monthly
Annual subscription rates:
Individual \$125.00 (U.S.) - \$135.00 (Other countries)
Institution \$173.00 (U.S.) - \$205.00 (Other countries)

Published by

J. B. Lippincott

A **Wolters Kluwer** Company



Journals Division
J. B. Lippincott
227 East Washington Square
Philadelphia, PA 19106-3780

AIDS

THE NUMBER 1 JOURNAL
ON ALL ASPECTS OF AIDS

SCI® JOURNAL CITATION REPORTS® 1993
JOURNALS RANKED BY IMPACT FACTOR WITHIN CATEGORY

RANK	TITLE	IMPACT FACTOR
	INFECTIOUS DISEASES	
1	AIDS	6.089
2	J INFECT DIS	5.499
3	AIDS RES HUM RETROV	4.488

☐ Please enter my order for AIDS Vol 8, 12 issues

Personal Institutional Pre-reg doctors*
☐ £89.95 ☐ £179.95 ☐ £59.95
☐ US\$134.95 ☐ US\$269.95 ☐ US\$99.95

Add postage

☐ £15 (UK) ☐ £25 (Europe) ☐ £32 (RoW)
☐ US\$16 (N Am) ☐ US\$55 (S Am)

Total amount payable

☐ Am Ex ☐ VISA ☐ MasterCard

Signature Date

Card No. Exp Date

☐ Cheque/Eurocheque enclosed payable to Current Science Ltd

☐ Please invoice me (institutional subscriptions only)

☐ Bank Transfer - Add 20% to cover bank charges
Current Science Ltd, Acct No: 0056750/sort: 30-93-68
Lloyds Bank Plc, Great Portland Street, London W1A 4LN, UK
Please include details of name and address with payment advice.
*Pre-reg doctors may only subscribe at the discounted rate for two years.

Name

.....

Address

.....

.....

Post/zipcode

Country

.....

Telephone

Fax

.....

EU customers may be liable to pay VAT at the applicable rate.

Your VAT Registration No:

Our VAT Registration No:

..... GB466247723

For subscriptions in Japan contact: Nankodo Co. Ltd, 42-46, Hongo, 3-Chome,
Bunkyo-Ku, Tokyo 113 Japan.

No Risk Guarantee: Your money will be refunded in full if you cancel within 30 days of
receiving your order. You must return all goods received undamaged.

Return to: Current Science Ltd, 34-42 Cleveland Street, London, W1A 4LN, UK Tel: +44 (0)71 323 0323 Fax: +44 (0)71 580 1938

GUM1


THE UNACCEPTABLE FACE OF SCIENCE

Fraud exists, both in academic medical research and in drug trials in general practice. This important new book sets out the evidence, reviewing events since 1975 when the first notorious case of fraud became public knowledge.

The problem is viewed from many perspectives, with contributions from a general practitioner; head of an academic unit, contract research company director; statistician, editor and lawyer. Together, their information provides a compelling account of the extent to which fraud and misconduct have been and continue to be practised in medicine.

Contents include:

- Fraud in general practice
- Statistical aspects of detection
- The British Pharmaceutical Industry's response
- Legal aspects
- The French scene
- The Danish scene
- Data audits in trials and their implications for misconduct (USA)
- Fraud and the editor



Fraud and Misconduct in Medical Research is a valuable practical text for all researchers – and ultimately anyone who practises medicine.

Publication date: January 1993

Price: UK £24.95; Overseas £27.00 (including postage by air abroad)

BMA Members Price: UK £22.95; Overseas £25.00 (including postage by air abroad)

ISBN: 0-7279-0757-3

Also available

A Difficult Balance: Editorial Peer Review in Medicine

Third Impression (1991)

Price: UK £12.95; Overseas £15.50 (including postage by air abroad)

BMA Members Price: UK £11.95; Overseas £14.50 (including postage by air abroad)

ISBN: 0-7279-0310-1

BMJ
PUBLISHING GROUP



ORDER FORM **British Medical Journal, PO Box 295, London WC1H 9TE**

Please send me the following books:

QTY	Title	Amount
Please send me the following books:		Total £

Name _____

Address _____

Postcode _____


Cheque enclosed (made payable to British Medical Journal) £ _____ Membership No. _____

Debit my AMERICAN EXPRESS VISA MASTERCARD Card No. _____

Expiry date _____ Signature _____

BMJ is a member of the British Medical Association. For more information, contact the BMA at 11, St Andrews Place, Regents Park, London NW1 2NU.

Abbreviated prescribing information for DIFLUCAN* (fluconazole) Presentation: Capsules containing 50mg, 150mg or 200mg fluconazole; intravenous infusion containing fluconazole 2mg/ml in 0.9% sodium chloride solution; Powder for Oral Suspension available as two dosage strengths containing either fluconazole 50mg/5ml or 200mg/5ml on reconstitution with 24ml water. **Indications and dosage:** Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Dermal fungal infections: 50mg once daily for up to 6 weeks (usually 2-4 weeks - see data sheet). Vaginal candidiasis: single 150mg dose. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. **Administration:** DIFLUCAN may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. **Contra-indications:** Hypersensitivity to fluconazole or related azoles, pregnancy and women of childbearing potential unless adequate contraception is employed. **Warnings:** Lactation: Not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. **Drug interactions:** Anticoagulants, cyclosporin, oral sulphonylureas, phenytoin, rifampicin or theophylline. **Side-effects:** Nausea, abdominal discomfort, diarrhoea, flatulence and rarely anaphylaxis. **Legal Category:** POM. **Basic NHS Cost and Package Quantities:** DIFLUCAN capsules in calendar packs containing 7 x 50mg (£16.61, PL 57/0289), 7 x 200mg (£66.42, PL 57/0317) or 1 x 150mg (£7.12, PL 57/0290); Powder for Oral Suspension, 35ml bottle of 50mg/5ml (£16.61, PL 57/0343), 35ml bottle of 200mg/5ml (£66.42, PL 57/0344); Intravenous Infusion: 25ml (50mg) bottle (£7.32, PL 57/0315), 100ml (200mg) bottle (£29.28, PL 57/0315). Hospital prices are available on request. **References:** 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. *et al.* (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. *et al.* (1991), *Journal of Infection*, 23, 17-31. *Trade Mark. Further information on request. **Pfizer Limited**, Sandwich, Kent.



DIFLUCAN* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.¹ It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.^{2,3} DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.⁴ Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.⁵

Diflucan* ORAL/I.V. Counters invasive fungal infection
fluconazole *Trade Mark